Brokerages Set Voyager Therapeutics Inc (NASDAQ:VYGR) Target Price at $26.17

Voyager Therapeutics Inc (NASDAQ:VYGR) has been given an average rating of “Hold” by the eleven analysts that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $26.80.

VYGR has been the topic of several research analyst reports. Wedbush restated an “outperform” rating on shares of Voyager Therapeutics in a research report on Wednesday, November 6th. Zacks Investment Research downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, November 9th. Morgan Stanley lowered their price objective on Voyager Therapeutics from $28.00 to $26.00 and set an “equal weight” rating on the stock in a research report on Friday, October 11th. Cowen restated a “buy” rating on shares of Voyager Therapeutics in a research report on Wednesday, November 6th. Finally, Evercore ISI reiterated a “hold” rating and issued a $18.00 target price on shares of Voyager Therapeutics in a research report on Sunday, November 24th.

Shares of Voyager Therapeutics stock opened at $13.69 on Friday. The stock’s 50-day simple moving average is $13.88 and its 200-day simple moving average is $18.07. Voyager Therapeutics has a 52 week low of $7.76 and a 52 week high of $28.79. The company has a market capitalization of $499.38 million, a price-to-earnings ratio of -4.98 and a beta of 2.47.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.41) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.83) by $0.42. Voyager Therapeutics had a negative return on equity of 57.32% and a negative net margin of 72.64%. The business had revenue of $20.43 million for the quarter, compared to the consensus estimate of $3.94 million. Analysts forecast that Voyager Therapeutics will post -1.6 earnings per share for the current year.

Several large investors have recently bought and sold shares of the stock. Invesco Ltd. increased its stake in Voyager Therapeutics by 643.6% during the second quarter. Invesco Ltd. now owns 421,155 shares of the company’s stock worth $11,464,000 after acquiring an additional 364,516 shares during the last quarter. Nuveen Asset Management LLC bought a new stake in Voyager Therapeutics during the second quarter worth approximately $7,009,000. Renaissance Technologies LLC increased its stake in Voyager Therapeutics by 48.2% during the second quarter. Renaissance Technologies LLC now owns 729,801 shares of the company’s stock worth $19,865,000 after acquiring an additional 237,500 shares during the last quarter. State Street Corp increased its stake in Voyager Therapeutics by 16.7% during the third quarter. State Street Corp now owns 1,410,787 shares of the company’s stock worth $24,280,000 after acquiring an additional 202,283 shares during the last quarter. Finally, BlackRock Inc. increased its stake in Voyager Therapeutics by 9.8% during the second quarter. BlackRock Inc. now owns 2,079,554 shares of the company’s stock worth $56,605,000 after acquiring an additional 185,582 shares during the last quarter. Institutional investors own 81.92% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.

Featured Article: Most Active Stocks: Dollar Volume vs Share Volume

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.